Pharvaris (PHVS) Liabilities and Shareholders Equity (2019 - 2026)

Pharvaris (PHVS) has 8 years of Liabilities and Shareholders Equity data on file, last reported at $304.1 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 16.56% year-over-year to $304.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 billion (changed 0.49% YoY) and the FY2025 annual result came in at $340.6 million, up 8.0% from the prior year.
• Liabilities and Shareholders Equity declined to $304.1 million in Q1 2026, from $350.9 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $429.0 million in Q4 2023 to a low of $158.6 million in Q1 2023.
• A 5-year average of $282.0 million and a median of $260.9 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity jumped 158.58% — and 2025, when it plunged 37.32%.
• Tracing PHVS's Liabilities and Shareholders Equity over 5 years: stood at $171.1 million in 2022, then surged by 150.67% to $429.0 million in 2023, then fell by 27.42% to $311.4 million in 2024, then advanced by 12.7% to $350.9 million in 2025, then slipped by 13.33% to $304.1 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $304.1 million (Q1 2026), $350.9 million (Q4 2025), and $396.2 million (Q3 2025), per Business Quant data.